You are here: Industry Insights > Breakthrough Therapy

News List

Weekly Pharma News Review | PharmaSources.com (April 11 to 15) Yefenghong
April 20, 2022
The sharp crushing in the stock prices of Chinese vaccine leader companies Zhifei Biological and Wantai Biological is the most-watched news this week.
Breakthrough Therapy for Type 2 Immune Indications: the Ten Billion dollars drug Dupilumab will be marketed in China PharmaSources/1℃
June 19, 2020
Sanofi explained in detail the mechanism of action of Dupilumab and its clinical benefit in type 2 immune indications at a recent R&D conference.
Savara Granted Breakthrough Therapy Designation for Molgradex americanpharmaceuticalreview
January 07, 2020
Savara announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.
AstraZeneca announces breakthrough therapy status for Calquence in CLL pharmaceutical-technology
August 15, 2019
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL).
CALQUENCE Granted US Breakthrough Therapy Designation americanpharmaceuticalreview
August 15, 2019
AstraZeneca announced the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for CALQUENCE® (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the most common
Eisai, Merck receive breakthrough therapy designation from FDA biospectrumasia
July 23, 2019
For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1 worldpharmanews
April 03, 2019
The Association of the British Pharmaceutical Industry has called for a temporary ban on drugs exports in the event of a no-deal Brexit to prevent the NHS being hit by shortages…
FDA grants breakthrough therapy status to crizanlizumab pharmaceutical-technology
January 10, 2019
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.
FDA grants breakthrough therapy status to crizanlizumab pharmaceutical-technology
January 10, 2019
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.....
FDA grants breakthrough therapy status for Novartis' crizanlizumab to prevent vaso-occlusive crises in sickle cell disease firstwordpharma
January 09, 2019
Novartis announced Tuesday that the FDA granted crizanlizumab a breakthrough therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD). Samit Hirawat, head of oncology global drug de

Previous page 1 2 Next page